Introduction

EXCLI J

EXCLI Journal

1611-2156

Leibniz Research Centre for Working Environment and Human Factors

2025-8617

10.17179/excli2025-8617

Doc1352

Review article

IFN-gamma in the tumor microenvironment: dual roles in cancer progression and therapy

Cui

Jiahui

1 Zhang

* 1 2 3 4 5 Yang

1 2 3 4

1Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China 2Zhongyuan Cell Therapy and Immunotherapy Laboratory, Henan Academy of Innovations in Medical Science, Zhengzhou, Henan, China 3School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China 4State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China 5School of Public Health, Zhengzhou University, Zhengzhou, Henan, China

*To whom correspondence should be addressed: Yi Zhang, Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, E-mail: yizhang@zzu.edu.cn

14 10 2025

2025

24 1352 1371 02 06 2025 10 09 2025

2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0/) You are free to copy, distribute and transmit the work, provided the original author and source are credited.

This article is available from https://www.excli.de/vol24/excli2025-8617.pdf

Interferon-gamma (IFN-γ), as a pleiotropic cytokine, plays a pivotal role in antitumor immunity. Its remarkable immunostimulatory, antiproliferative, and pro-apoptotic effects make it a promising candidate for tumor immunotherapy. Here, we highlight the dual role of IFN-γ in the tumor microenvironment during tumor development and treatment. IFN-γ can enhance antigen presentation, boost cytotoxic T cell and natural killer cell activity, and inhibit angiogenesis, promoting tumor regression and correlating with favorable therapeutic outcomes. However, prolonged exposure may induce the upregulation of immune checkpoint molecules such as programmed death-ligand 1, trigger T cell exhaustion, and recruit regulatory T cells, phenomena associated with the development of treatment resistance in cancer therapy. This dual nature poses significant challenges for harnessing IFN-γ in tumor treatment, necessitating an in-depth understanding of its mechanisms within specific microenvironments. Although numerous studies have explored IFN-γ-based tumor therapies, their outcomes have been inconsistent. Thus, although IFN-γ-based therapeutic strategies hold considerable promise, their clinical translation requires precise modulation to fully exploit its antitumor effects while mitigating potential protumor risks.

See also the graphical abstract(Fig. 1).

IFN-gamma tumor regression tumor progression immunoregulation immunotherapy

Introduction

Interferon-gamma (IFN-γ), encoded by the IFNG gene, is a dimeric protein composed of two antiparallel polypeptide chains (Zaidi and Merlino, 2011[133]). It exerts pleiotropic immunomodulatory effects spanning both innate and adaptive immune responses (Ding et al., 2022[27]). Studies have shown that IFN-γ can directly trigger tumor cell senescence (Ahmetlic et al., 2021[2]) and enhance antitumor immunity (Andrews et al., 2024[5]). CD4+ T cell-derived IFN-γ can reprogram tumor-associated macrophages (TAMs) to eliminate MHC-I-deficient tumors (Kruse et al., 2023[58]). Notably, the effectiveness of immune checkpoint blockade (ICB) therapy is partially determined by IFN-γ signaling pathway, as ICB-resistant tumors frequently harbor mutations in this pathway (Shen et al., 2022[103]). Immunologically, IFN-γ extends to both tumor cells (through MHC-I upregulation) and immune cells (via macrophage activation and dendritic cell cross-presentation), working synergistically to promote CD8+ T cell antigen recognition (Garris et al., 2018[34]). However, recent evidence reveals time-dependent effects: prolonged IFN-γ signaling may activate protumor immune programs (Qiu et al., 2023[92]). Clinically, although IFN-γ-based therapeutic regimens have been partially implemented for some time, their efficacy demonstrates significant interindividual variability (Schmeler et al., 2009[99], Zibelman et al., 2023[139]).

A complete interpretation of the principles of molecular mechanisms underlying IFN-γ-dependent antitumor and protumor effects, as well as its dual roles in patients with cancer, is critical for optimizing IFN-γ-based immunotherapy strategies. The focus of future research should lie in dissecting the dynamic regulatory mechanisms of IFN-γ during tumor evolution and clarifying its precise therapeutic targets, thereby providing a theoretical foundation for clinical translation.

This unique "double-edged sword" characteristic makes IFN-γ a focal point in cancer immunology research. This review comprehensively examines the dual roles of IFN-γ in tumor progression and therapy.

IFN-γ Production and Regulation

As a critical cytokine linking innate and adaptive immune responses (Ding et al., 2022[27]), IFN-γ production in innate immunity primarily originates from natural killer (NK) cells (Sun et al., 2024[110]). In adaptive immunity, CD8+ and CD4+ T-cell subsets serve as major IFN-γ producers (Alspach et al., 2019[4], Rydyznski Moderbacher et al., 2022[96]). Other sources include certain antigen-presenting cells (APCs), such as dendritic cells, macrophages, and B cells (Burke and Young, 2019[13]). IFN-γ production must be tightly regulated through both positive and negative mechanisms in immune cells. These IFN-γ-producing cells are stimulated by interleukins (IL-12, IL-15, IL-18, and IL-21) (Kannan et al., 2011[52], Strengell et al., 2003[109]), antigens released by tumors or pathogens (Ma et al., 2023[72], Yu et al., 2024[131]), in some cases, IFN-γ itself via a positive feedback loop (Alspach et al., 2019[4]). Specific cell types and inductive signals appear to determine distinct transcription factors to initiate IFN-γ transcription. For example, IL-12 binding to its receptor on CD4+ T cells (Lu et al., 2022[69]) activates JAK2 and TYK2, leading to STAT4 phosphorylation, enhanced transcriptional activity (Thierfelder et al., 1996[112]) and subsequently, IFN-γ and IL-12Rβ2 upregulation, reinforcing IL-12 responsiveness (Afkarian et al., 2002[1]). IFN-γ promotes antigen-presenting cell (APC)-derived IL-12 secretion, creating a positive feedback loop (Garris et al., 2022[35]) (Figure 2(Fig. 2)). NKR in NK cells or TCR in T cells (Kannan et al., 2011[52]) triggers receptor signaling, activating the Src/MAPK/ERK/p38 pathway (Schoenborn and Wilson, 2007[100]). This cascade induces IFNG expression via T-bet, STAT4, AP-1, Fos, Jun, and Eomes (Jorgovanovic et al., 2020[50]).

Overall, IFN-γ production results from the synergistic effects of multiple stimulating factors. Subsequent studies are needed to comprehensively clarify the initiating signals and transcriptional regulatory mechanisms underlying its generation.

IFN-γ Signaling Pathways

IFN-γ, a pivotal cytokine bridging innate and adaptive immunity (Ding et al., 2022[27]), exerts its biological functions through intricate signaling networks. These pathways encompass not only the canonical JAK-STAT cascade (Ealick et al., 1991[28]) but also non-canonical regulatory mechanisms (Yu et al., 2022[132]). A comprehensive dissection of IFN-γ-mediated signaling is crucial to fully understand its dual roles in tumor progression and therapeutic intervention.

JAK-STAT pathway

IFN-γ biological activity and signaling depend on its receptor, IFNγR, which comprises two IFNγR1 and IFNγR2 chains each (Ding et al., 2022[27]). In the classical IFN-γ/IFNγR/JAK/STAT pathway, IFN-γ binds to IFNγR as an antiparallel dimer (Ealick et al., 1991[28]). JAK1 and JAK2 are respectively linked to the intracellular domains of IFNγR1 and IFNγR2. Upon ligand binding, the receptors undergo phosphorylation (Zaidi and Merlino, 2011[133]), and IFNγR2 transmits signals that promote IFNγR1-IFN-γ complex internalization. Accompanied by the translocation of the IFNγR1 extracellular domain into the intracellular compartment, JAK2 translocates from IFNγR2 to IFNγR1 owing to its stronger binding affinity for IFNγR1 (Johnson et al., 2011[49]). Activated JAK1 and JAK2 subsequently phosphorylate the intracellular domain of IFNγR1, thereby generating binding sites for STAT1 recruitment (Zaidi and Merlino, 2011[133]). Phosphorylated STAT1 translocates to the nucleus and binds to gamma-activated sequence (GAS) elements, thereby initiating target gene transcription (Sekrecka et al., 2023[101]).

IFN-γ-induced genes are collectively referred to as interferon-stimulated genes (ISGs), many of which are transcription factors that can further regulate effector gene expression (Liu et al., 2019[67]). The expression of these functionally diverse ISGs significantly influences IFN-γ stimulation outcomes (Han et al., 2023[42]).

The IFN-γ/IFNγR/JAK/STAT signaling pathway is stringently regulated at multiple levels. At the regulatory level of IFNGR, transcription factors NFκB, EGR, and SP1 enhance IFNGR mRNA expression (Chen et al., 2012[18]), while AP2 and IRF2 exert inhibitory effects (Chen et al., 2012[18], Wang et al., 2008[120]). Negative regulation of JAK activity is mediated by the suppressor of cytokine signaling (SOCS) proteins and small-molecule inhibitors (Liau et al., 2018[66]), whereas APLNR is essential for its normal function (Liu et al., 2022[68]). The regulatory mechanisms of STAT1 activity include: post-translational modifications mediated by PIAS (Niu et al., 2018[81]), A20 (Breitenecker et al., 2021[10]), and CBP/TCP45 (Krämer et al., 2009[57]); PRMT1-mediated regulation independent of phosphorylation status (Mowen et al., 2001[77]); and the proteasomal degradation pathway (Li et al., 2021[61]). STAT1 promoter activity can be suppressed by methylation (Xu et al., 2022[128]) or activated through HDAC3-mediated deacetylation (Yang et al., 2022[130]) (Figure 3(Fig. 3)).

In addition to the classical pathway, IFN-γ also has non-classical signal transduction pathways (Jorgovanovic et al., 2020[50]). Whether these pathways function synergistically or independently requires further investigation. In view of the significant role of IFN-γ signaling in tumor immunity, a comprehensive understanding of these regulatory mechanisms is of great importance.

Non-canonical IFN-γ -activated pathway

IFN-γ exerts differential effects depending on exposure duration and concentration. Acute high-dose exposure induces growth arrest and apoptosis, whereas chronic low-dose exposure promotes cell survival (Cheon et al., 2023[20]). Our previous studies in the tumor microenvironment (TME) of non-small cell lung cancer revealed that IFN-γ concentration determines pathway activation: high doses trigger classical JAK/STAT signaling, whereas low doses activate ICAM1-PI3K-Akt-Notch1 cascade, increasing CD133 expression and cancer stemness (Song et al., 2019[108]). IFN-γ induces the upregulation of programmed death-ligand 1 (PD-L1) through both JAK/STAT (Han et al., 2023[42]) and PI3K-Akt pathways (Gao et al., 2018[33]). Although JAK2-mediated STAT1 phosphorylation drives gene transcription, PI3K-Akt modulates STAT1 phosphorylation levels. PI3K inhibition significantly reduces ISG expression (CXCL9/10, PD-L1), suggesting crosstalk between these pathways (Gao et al., 2018[33]). The hyperactivated PI3K/Akt/mTOR pathway (Yu et al., 2022[132]), enhances STAT1-induced ISG transcription via mTOR/p70S6K-mediated mRNA translation (Kaur et al., 2008[53]), suggesting that IFN-γ-mediated PI3K-Akt activation may amplify effector protein production (Figure 3(Fig. 3)).

Dual Roles of IFN-γ on Tumor Progression

The dual effects of IFN-γ have attracted widespread attention, motivating numerous mechanistic investigations by researchers. Although many significant findings have been obtained, numerous questions remain unaddressed. Here, by discussing previously published research outcomes, we provide insights into how IFN-γ exerts its dual effects on tumors (Figure 4(Fig. 4)).

Anti-tumor effects of IFN-γ

IFN-γ exerts antitumor effects through dual mechanisms: direct action on tumor cells and TME modulation. In tumor cells, IFN-γ suppresses proliferation by inducing apoptosis (Chaudhari et al., 2024[17]) and senescence (Homann et al., 2022[44]) while inhibiting invasion and metastasis (Chaudhari et al., 2024[17]) and reversing drug resistance (Espinosa-Carrasco et al., 2024[30]). Immunologically, IFN-γ recruits immune cells into the TME (Gocher et al., 2022[39]), promotes Th1 polarization of CD4⁺ T cells while suppressing Th2/Th17 differentiation (Gocher et al., 2022[39]) and enhances CD8⁺ T cell cytotoxicity (Shen et al., 2023[104]). Further, it drives macrophage polarization toward the M1 phenotype (Gocher et al., 2022[39]) and facilitates germinal center formation in B cells via BCL6 (Jackson et al., 2016[47]).

Promoting tumor cell apoptosis

Research on apoptosis is intricately linked to oncology (Moyer et al., 2025[78]). The terminology for the concept of "apoptosis" was coined over five decades ago following its discovery in both healthy tissues and malignant tumors. Apoptosis is essential not only for the maintenance of tissue homeostasis but also for tumor growth and therapy-induced tumor regression (Kerr et al., 1972[54]). The TRIM family proteins, possessing E3 ubiquitin ligase activity, play pivotal roles in diverse cellular processes including innate immunity, autophagy, intracellular signaling, and carcinogenesis (Hatakeyama, 2017[43]). In lung cancer, TRIM proteins can function as either tumor suppressors or oncogenes by modulating various signaling pathways (Zhan and Zhang, 2021[136]). Recent findings demonstrate that IFN-γ upregulates TRIM34 expression, which promotes apoptotic signaling through key regulators, thereby reducing tumor viability (Chaudhari et al., 2024[17]).

Activating and maintaining senescence programs in tumor cell

Cellular senescence includes oncogene activation or mitochondrial dysfunction (Gorgoulis et al., 2019[41], Lian et al., 2020[65]). Senescent cells demonstrate prominent characteristics encompass metabolic dysregulation, stable cell cycle arrest, enhanced secretory activity, elevated senescence-associated β-galactosidase (SA-β-gal) activity, and macromolecular damage (Gorgoulis et al., 2019[41], Ou et al., 2021[84]). Another defining characteristic of senescent cells is their secretion of diverse bioactive molecules, collectively termed the senescence-associated secretory phenotype (SASP) (Birch and Gil, 2020[9]). In senescent melanoma cells, cell cycle arrest is predominantly mediated by p21 (Engeland, 2022[29]). Research indicates that cytokine-induced senescence (CIS) serves as a core mechanism underlying the antitumor effects of various immunotherapies (Brenner et al., 2020[11]). Recent comparative studies between CIS (IFN-γ+TNF treatment) and therapy-induced senescence (TIS, doxorubicin/palbociclib treatment) in melanoma models revealed that all treatments induced stable growth arrest and boosted SA-β-gal activity, with all except palbociclib significantly promoting p21 upregulation. Notably, CIS-stimulated SASP factor expression and secretion levels were several-fold stronger than TIS. Experiments confirmed that conditioned media from either cytokine or palbociclib treatments could induce senescence features in melanoma cells, suggesting that IFN-γ and TNF may establish a self-sustaining senescence surveillance system to inhibit tumor progression (Homann et al., 2022[44]).

Inhibiting tumor invasion and metastasis

Cancer metastasis represents a critical global public health challenge, characterized by its highly heterogeneous biological nature (Traba et al., 2021[113]). Despite extensive research, developing targeted therapies against metastatic seeding and colonization remains an unresolved scientific frontier in oncology (Bergers and Fendt, 2021[7]). Consequently, elucidating the molecular mechanisms governing tumor cell dissemination and metastatic outgrowth holds profound scientific significance (Lyden et al., 2022[71]). The lymphatic system is a major route for melanoma dissemination, facilitating tumor cell spread to draining lymph nodes (Dieterich et al., 2022[26]). Lymphatic integrity, maintained through the proper organization of junctional proteins in lymphatic vessels (Dieterich et al., 2019[25]), represents a critical barrier against tumor metastasis. Recent mechanistic studies reveal that IFN-γ suppresses melanoma cell trans-lymphatic endothelial migration through a novel pathway involving AMPK signaling inhibition and subsequent upregulation of tight junction protein Claudin-3 in lymphatic endothelial cells (LECs) (Zhu et al., 2024[138]). Furthermore, emerging evidence from lung cancer research indicates that TRIM34 activation mediated by IFN-γ may effectively inhibit metastatic progression by compromising cancer cell migratory and invasive capacities (Chaudhari et al., 2024[17]).

Remodeling TME and overcoming ICB resistance

ICB therapy can elicit remarkable clinical responses across multiple cancer types; however, the development of resistance to this treatment approach remains prevalent (Patel and Minn, 2018[85], Shan et al., 2022[102]). In melanoma, studies have demonstrated that IFN-γ modulates immune responses following immune checkpoint inhibitor (ICI) therapy (Yamazaki et al., 2017[129]). Currently approved ICIs for patients with melanoma are as follows: (Gocher et al., 2022[39]) anti-programmed death 1 (PD-1) antibodies nivolumab and pembrolizumab, anti-PD-L1 atezolizumab (Mendoza et al., 2019[76]), anti- cytotoxic t-lymphocyte-associated protein 4 (CTLA-4) lpilimumab (Ding et al., 2022[27]), and anti-lymphocyte activation gene 3 (LAG-3) relatlimab. PD-1 inhibition elevates IFN-γ levels at tumor sites, enhancing chemokine-dependent immune cell trafficking to melanoma lesions (Peng et al., 2012[88]). Under the influence of ICIs, IFN-γ regulates inflammatory and immune responses by increasing MHC expression and antigen presentation, influencing TAMs and DCs, and promoting Th1 cell responses; however, counter-regulatory mechanisms that attenuate anti-tumor immunity are also involved (Ivashkiv, 2018[46]). Elevated IFN-γ secretion has been shown to determine effective ICI responses in melanoma through comprehensive CD8+ T cell reprogramming (Espinosa-Carrasco et al., 2024[30]). Recent studies in murine melanoma models revealed that CD8+ T cells lacking PD-1 and LAG-3 demonstrate more potent tumor clearance due to increased IFN-γ secretion (Andrews et al., 2024[5]). Furthermore, combined administration of nivolumab and relatlimab potentiates CD8+ T cell differentiation by enhancing TCR signaling and IFN-γ pathway responses, correlating with augmented T cell effector functions (Cillo et al., 2024[22]).

Pro-tumor effects of IFN-γ

IFN-γ may paradoxically promote tumor progression under certain conditions. Notably, IFN-γ can recruit myeloid-derived suppressor cells (MDSCs) to facilitate tumor growth (Theivanthiran et al., 2020[111]). Moreover, IFN-γ stimulation enhances regulatory T cell (Treg) infiltration while impairing the cytotoxicity of T cells (CTLs) (Xie et al., 2023[126]). Moreover, it disrupts the tumor immune microenvironment by suppressing the maintenance of stem-like properties in intratumoral T cells (Mazet et al., 2023[74]). Remarkably, IFN-γ can directly exert effects on tumor cells to promote their survival and induce stemness properties. (Song et al., 2019[108]). It significantly upregulates PD-L1 (Falcinelli et al., 2023[31], Wu et al., 2024[125]) and indoleamine 2,3-dioxygenase (IDO) expressions (Schalper et al., 2017[98]) in tumor cells, and drives malignant transformation (Choi et al., 2022[21]). These changes ultimately drive immune evasion and subsequent tumor progression (Pedrosa et al., 2024[87], Wu et al., 2024[125]).

Promoting cancer stem cell (CSC) properties

CSCs represent a rare population of malignant cells characterized by self-renewal capacity, pluripotency, immune privilege, high tumorigenicity, and longevity. The stem-like traits and tumorigenic potential of CSCs are partially determined by constitutive activation of highly conserved signaling pathways, including Notch, Wnt, and Hedgehog cascades (Chen et al., 2011[19]). The emerging concept of "CSC immunology" has revealed that CSCs depend on a specialized immune niche for their maintenance. In hepatocellular carcinoma (HCC), liver cancer stem cells have been identified as the primary drivers of therapy resistance, metastasis, and tumor recurrence (Nassar and Blanpain, 2016[80]). Notably, accumulating evidence demonstrates an association between the tumor-promoting effects of IFN-γ and CSC regulation. IFN-γ exposure upregulates the expression of stemness markers CD133 and CD44 in tumor cells, providing novel mechanistic insights into IFN-γ-mediated oncogenesis (Li et al., 2024[62]).

Upregulating PD-L1 and IDO-1 expressions

The PD-L1 signaling pathway performs a significant function in tumor immunoregulation (Majidpoor and Mortezaee, 2021[73]). The molecular mechanism of this pathway involves PD-1, which triggers downstream suppressive signals upon binding to its ligand PD-L1, leading to T cell exhaustion and functional impairment (Majidpoor and Mortezaee, 2021[73], Ping et al., 2024[89]). Within the TME, overexpression of PD-L1 in both tumor cells and antigen-presenting cells represents a critical mechanism of immune evasion. Notably, IDO-1, a key enzyme in tryptophan metabolism, effectively suppresses immune cell functions, including T lymphocytes, by depleting local tryptophan in the microenvironment (Platten et al., 2014[90]). In lung cancer animal models, IDO-1 has been demonstrated to exert dual effects of promoting immunosuppression and tumor progression (Smith et al., 2012[106]). Research indicates that IFN-γ stimulation can simultaneously upregulate both PD-L1 and IDO-1 expressions (Schalper et al., 2017[98]), indicating that this synergistic effect may constitute an important molecular basis for its tumor-promoting activity.

Promoting malignant phenotypic transformation and tumor progression

Intratumoral heterogeneity (ITH) significantly compromises the efficacy of anticancer therapies by mediating treatment escape mechanisms and has been established as a key driver of therapeutic failure (Vitale et al., 2021[118]). Lineage plasticity, serving as a core mechanism underlying ITH development (Bhat et al., 2024[8]), is increasingly acknowledged as a defining feature of cancer (Mehta and Stanger, 2024[75]). Although most muscle-invasive bladder cancers (MIBCs) are pathologically classified as urothelial carcinomas, they consistently exhibit significant heterogeneity at both morphological and molecular levels (Warrick et al., 2019[121]). Recent studies have stratified MIBC into six distinct transcriptional subtypes: luminal, luminal nonspecified, luminal unstable, stroma-enriched, basal/squamous (Ba/Sq), and neuroendocrine-like subtypes (Kamoun et al., 2020[51]). Notably, emerging evidence demonstrates that IFN-γ/JAK1/STAT1 signaling pathway activation drives the transition from luminal MIBC to the more aggressive Ba/Sq subtype by downregulating forkhead box A1 (FOXA1) expression in urothelial cells (Lawrence et al., 2025[59]).

Guanylate-binding protein 1 (GBP1), a GTPase, serves as a downstream effector of the IFN-γ signaling pathway (Prakash et al., 2000[91]). Current research demonstrates that IFN-γ in the breast TME upregulates GBP1 expression through activation of the IFN-γ-STAT1 signaling axis, thereby facilitating their transendothelial migration across the blood-brain barrier (BBB) (Pedrosa et al., 2024[87]). However, the IFN-γ pathway alone is insufficient to fully mediate efficient BBB penetration, as additional signaling pathways beyond IFN-γ contribute to promoting breast cancer cell migration across the BBB (Pedrosa et al., 2024[87]). Notably, the C-X-C motif chemokine ligand 9/10/11 (CXCL9/10/11)- C-X-C motif chemokine receptor 3 axis, which relies on IFN-γ activity, is highly expresse in primary breast tumors from patients with subsequent brain metastases. These findings collectively indicate that the IFN-γ signaling pathway has a substantial impact on the establishment of estrogen receptor-positive (ER+) breast cancer brain metastases (Pedrosa et al., 2024[87]).

Inducing immunosuppressive microenvironment formation

Excessive or sustained IFN-γ signaling activation may lead to IFN-γ-dependent pathway dysregulation, fostering the development of an immunosuppressive TME (Wawrzyniak and Hartman, 2025[122]). Within the TME, IFN-γ causes the Nod-like receptor protein 3 (NLRP3) inflammasome to be activated, accompanied by the concurrent release of heat shock protein 70 and the Wnt ligand WNT-5a (Theivanthiran et al., 2020[111]). WNT-5a further activates the Hippo/Yes-associated protein signaling pathway, triggering upregulation of C-X-C motif chemokine receptor 2 and promoting MDSC recruitment (Theivanthiran et al., 2020[111]). Furthermore, IFN-γ suppresses the maintenance and functional diversity of stem-like T cells within tumors, collectively impairing antitumor immune responses. It also downregulates the expression of NAD(P)-dependent steroid dehydrogenase-like protein (NSDHL), subsequently promoting TGF-β1 production. (Xie et al., 2023[126]). This process not only diminishes CTLs but also increases Treg infiltration, ultimately exacerbating the immunosuppressive state of the TME (Xie et al., 2023[126]).

Dual Roles of IFN-γ in Cancer Therapy

IFN-γ is a pivotal pleiotropic cytokine that not only orchestrates the crosstalk between innate and adaptive immunity (Ding et al., 2022[27]) but also demonstrates a paradoxical dual role in cancer immunotherapy. Recently, extensive research efforts have been devoted to synergistically enhance IFN-γ-mediated antitumor efficacy while mitigating its tumor-promoting effects. These advancements have not only provided novel approaches to address clinical challenges (including therapeutic resistance and toxicity) but have also laid a solid foundation for translating IFN-γ into clinical practice to improve patient outcomes. This review systematically summarizes key mechanistic insights and research progress to provide a theoretical framework for developing more precise immunotherapeutic strategies.

Exerting antitumor effects

Current studies have demonstrated that IFN-γ is capable of suppressing tumor development through various pathways (Chaudhari et al., 2024[17], Cheon et al., 2023[20], Homann et al., 2022[44]). Extensive recent studies aim to enhance its therapeutic effectiveness and address clinical obstacles. This review summarizes the antitumor mechanisms of IFN-γ and related research progress, these efforts are expected to facilitate clinical translation and improve prognosis for patients with cancer.

Combating breast cancer drug resistance and reprograming the TME

HER2-positive breast cancer represents is a particularly aggressive form of the disease (Li et al., 2024[64]). Although HER2-targeted therapy has significantly improved survival (Oh and Bang, 2020[83]), some patients fail to achieve pCR even with anti-HER2 neoadjuvant therapy (van Mackelenbergh et al., 2023[116]). Integrating HER2-targeted therapy with approaches that strengthen anti-HER2 Th1 immunity could lead to better outcomes for high-risk patients (Datta et al., 2016[23]), with IFN-γ being a key effector of Th1 immunity (Wen et al., 2025[123]). HER2 is normally degraded via the CUL5-mediated proteasomal pathway but can evade degradation by binding to Hsp90 (Pearl, 2005[86]). The Cdc37-Hsp90 complex functions as an essential molecular chaperone for HER2 stability and activity (Jia et al., 2021[48]). Recent findings show that IFN-γ disrupts the HER2-Cdc37-Hsp90 interaction, promoting CUL5-mediated HER2 breakdown and enhancing trastuzumab efficacy in resistant cells (Jia et al., 2021[48]).

Toll-like receptor (TLR) agonists have been explored as promising anticancer agents, (Rolfo et al., 2023[95]). As IFN-γ alone may be insufficient to optimally induce antitumor T cell and macrophage phenotypes and may require secondary signals from the microenvironment, combination with TLR agonists appears particularly suitable (Müller et al., 2017[79]). Research indicates that poly (γ-glutamic acid) (γ-PGA) nanoparticles (NPs) effectively trigger robust innate and adaptive immune responses (Uto et al., 2011[114]), while chitosan (Ch) activates the NLRP3 inflammasome to trigger robust IL-1β production (Bueter et al., 2011[12]). Ch/γ-PGA NPs have demonstrated synergistic effects with conventional radiotherapy in reducing systemic immunosuppression and tumor progression in 4T1 breast cancer models (Castro et al., 2020[16]), suggesting their potential as adjuvants for IFN-γ-based therapies. Recent findings in 4T1 orthotopic breast tumor models reveal the therapeutic synergy of combining Ch/γ-PGA NPs with IFN-γ. The combination therapy completely halted primary tumor growth throughout treatment and reduced pulmonary metastatic burden. Systemically, it decreased immunosuppressive myeloid cell percentages while increasing Th1 and cytotoxic T cell populations (Castro et al., 2025[15]). This combined approach represents a novel strategy for enhancing IFN-γ-based anticancer treatments.

Synergizing with STING agonist and ICB to enhance gastric cancer therapy

cGAS-STING pathway activation induces multiple antitumor effects, including immune response activation, interferon production, and tumor cell death. Consequently, tumor cells often suppress this pathway to evade immunity (Raaby Gammelgaard et al., 2021[93]). Although previous studies have highlighted the significant antitumor activity of the cGAS-STING pathway (Lv et al., 2024[70]), recent findings show that a triple therapy combining IFN-γ, STING agonist, and anti-PD-1 antibody significantly enhances cGAS/STING expression, IFN-β secretion, and tumor cell apoptosis. This combination therapy also synergistically activates multiple immune cell populations to boost antitumor immunity. These discoveries provide a novel strategy for GC immunotherapy and expand the therapeutic potential of IFN-γ-based tumor immunotherapy (Hosseinzadeh et al., 2024[45]).

Augmenting CD8+ T cell infiltration and cytotoxic activity in HCC

HCC poses considerable health risks (Zhang et al., 2024[137]). Tachykinins (substance P and NKA) and their receptors (NK1R/NK2R) are expressed not only in the nervous system but also in tumors (Nizam and Erin, 2018[82]). IFN-γ enhances T cell responses by upregulating NKA/NK2R expression in dendritic cells via STAT1 (Kitamura et al., 2012[55]). Recent findings indicates that IFN-γ enhances NK2R expression in CD8+ T cells via STAT1 signaling, while the absence of NK2R compromises their ability to combat tumors (Shen et al., 2023[104]). These results reveal the IFN-γ-STAT1-NK2R axis as a potential antitumor pathway.

Remodeling the TME of colorectal cancer and enhancing ICB sensitivity

Researchers have developed an engineered probiotic strain to enable targeted and prolonged IFN-γ release, preserving its immunostimulatory functions within malignant tissues (Li et al., 2024[60]). The team implemented a Synchronized Lysis Circuit (SLIC), which has a genomically integrated system enabling population-regulated IFN-γ delivery (SLIC-IFN-γ) (Savage et al., 2023[97], Vincent et al., 2023[117]). Research findings indicate that a single intratumoral administration of SLIC-IFN-γ enables targeted IFN-γ release in colorectal cancer models. When combined with bacterial adjuvants, this approach effectively stimulates myeloid cells, within both the TME and draining lymph nodes. Notably, IFN-γ monotherapy delivered via bacterial vectors exhibits potent antitumor activity in MHC-I-deficient and IFN-γ signaling-deficient models by activating NK cells. Furthermore, SLIC-IFN-γ enhances CD8+ T cell expansion in distant tumors and increases the sensitivity of advanced cancers to PD-1 blockade. No significant adverse effects have been observed. The combined strategy of PD-1 blockade with engineered bacterial-mediated IFN-γ delivery presents a promising avenue for cancer immunotherapy (Li et al., 2024[60]).

Combined chemotherapy enhances the killing effect on neuroblastoma

Neuroblastoma is responsible for roughly 10% of cancer-related fatalities in pediatric patients (Smith et al., 2010[107]). Combining chemotherapy with immunomodulators agents to leverage the innate immune system and potentially imporve therapeutic responses has remained a central focus of research in this field (Zeki et al., 2023[135]). Recent investigations have found the localized IFN-γ delivery to tumor sites via silk biomaterials can effectively inhibit neuroblastoma growth. Notably, combining IFN-γ with vincristine exhibits synergistic tumoricidal effects. These findings not only validate IFN-γ antitumor mechanisms but also provide novel insights for developing combination immunotherapy strategies against neuroblastoma (Zeki et al., 2023[135]) (Table 1(Tab. 1); References in Table 1: Castro et al., 2025[15]; Chaudhari et al., 2024[17]; Homann et al., 2022[44]; Hosseinzadeh et al., 2024[45]; Jia et al., 2021[48]; Li et al., 2024[60]; Shen et al., 2023[104]; Zeki et al., 2023[135]; Zhu et al., 2024[138]).

Attenuating pro-tumorigenic effects

Although IFN-γ exhibits significant potential in tumor immunotherapy, its potential tumor-promoting effects (Song et al., 2019[108]) still require focused attention and mitigation. Recent studies demonstrate that combination therapies can effectively attenuate IFN-γ-mediated protumorigenic effects, thereby improving both treatment safety and efficacy. These findings provide crucial evidence supporting the clinical translation of IFN-γ-based therapies (Xie et al., 2023[126]).

Counteracting IFN-γ-driven ICI resistance in liver cancer therapy

Studies indicate that NSDHL links cholesterol metabolism to tumor progression, with context-dependent pro- or anti-tumor effects (Gabitova-Cornell et al., 2020[32]). Regorafenib, a tyrosine kinase inhibitor, has been authorized for the treatment of hepatocellular carcinoma (HCC) in patients with sorafenib resistance (Gordan et al., 2024[40]). In HCC models, regorafenib-ICI combination enhances CD8+ T cell infiltration (Shigeta et al., 2020[105]). Recent studies indicate IFN-γ induced by ICIs suppresses NSDHL expression, which results in SREBP1 activation and elevated TGF-β1 production. This process diminishes T cell cytotoxicity while facilitating Treg infiltration, ultimately contributing to ICI resistance. Regorafenib counteracts this by modulating the IFN-γ/NSDHL/SREBP1/TGF-β1 axis, restoring ICI efficacy in HCC (Xie et al., 2023[126]), representing a novel strategy for overcoming IFN-γ-mediated immunosuppression in cancer therapy.

Inhibiting IFN-γ-mediated PD-L1 expression in multiple cancers

Traditional Chinese Medicine has been utilized worldwide for centuries in cancer treatment, with natural compounds-especially botanical extracts-continuing to serve as vital resources for innovative medical discoveries. Atractylodes macrocephala (AM), or "Baizhu" in Chinese, refers to the dried rhizome of AM Koidz, a perennial plant first recorded in the ancient text “Shennong Ben Cao Jing” over two millennia ago. This herb harbors a variety of bioactive substances (Li et al., 2022[63]), including the sesquiterpene lactones atractylenolide- II (AT-II) (Deng et al., 2021[24]). Experimental studies indicate that the combination of AT-II and IFN-γ therapy enhances the colorectal cancer immune-microenvironment by blocking IFN-γ-driven activation of the NF-κB p65/PD-L1 signaling pathway, effectively suppressing tumor progression and lung metastases (Wu et al., 2024[125]). This combination not only offers a novel immunotherapeutic approach but also provides a strategic solution for overcoming IFN-γ-mediated immunosuppressive resistance.

Triptolide, a natural compound, exhibits potent antitumor activity in cancer (Wu et al., 2024[124]). Using FDA-approved Pluronic F127 hydrogel, researchers co-delivered triptolide with IFN-γ. In triple-negative breast cancer, this combination showed deep tumor penetration, where triptolide blocked IFN-γ-induced PD-L1 upregulation, suppressing tumor growth (Cai et al., 2023[14]). The synergy enhanced antitumor CD8+ T cell responses, demonstrating a novel approach to modulate the dual effects of IFN-γ.

IFN-γ has demonstrated considerable therapeutic potential in cancer therapy, driving its clinical evaluation across diverse cancers. However, inconsistent trial results highlight the need to optimize its application for different tumor types (Table 2(Tab. 2); References in Table 2: Alberts et al., 2008[3]; Artis and Spits, 2015[6]; Gautam et al., 2022[36]; Reinisch et al., 2002[94]; Schmeler et al., 2009[99]; Vahdat et al., 2007[115]; Zarogoulidis et al., 2013[134]; Zibelman et al., 2023[139]).

Notes

Yi Zhang and Li Yang (Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; E-mail: fccyangl1@zzu.edu.cn) contributed equally as corresponding author.

DeclarationConsent for publication

Not applicable.

Competing interests

No potential conflicts of interest are disclosed.

Funding

This work was supported by grants from the National Natural Science Foundation of China (grant numbers 82350121, 82573155), Science and Technology Innovation Team Support Plan from Henan Province (grant number 25IRTSTHN039), Young and middle-aged Health Science and Technology Innovation Talents in Henan Province (grant number LJRC2024012), Outstanding Young Talents Project from Henan Province (grant number 2523004210210), Top Talent Plan from Zhengzhou University, and Funding for Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University (grant number ZYCXTD2023013).

Authors' contributions

Conceived and revised the review: Li Yang, Yi Zhang

Wrote the paper: Jiahui Cui

Declaration of Generative AI and AI-as sisted technologies in the writing process

During the preparation of this work the author(s) used DeepSeek to correct the grammatical and typographical errors in the manuscript.

Afkarian

Sedy

Yang

Jacobson

Cereb

Yang

T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells

Nat Immunol 2002 3 6 549 557 2

Ahmetlic

Fauser

Riedel

Bauer

Flessner

Hömberg

Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence

J Immunother Cancer 2021 9 1 e001660 3

Alberts

Marth

Alvarez

Johnson

Bidzinski

Kardatzke

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival

Gynecol Oncol 2008 109 2 174 181 4

Alspach

Lussier

Schreiber

Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity

Cold Spring Harb Perspect Biol 2019 11 3 a028480 5

Andrews

Butler

Cui

Cillo

Cardello

Liu

LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity

Cell 2024 187 16 4355 4372 6

Artis

Spits

The biology of innate lymphoid cells

Nature 2015 517 7534 293 301 7

Bergers

Fendt

The metabolism of cancer cells during metastasis

Nat Rev Cancer 2021 21 3 162 180 8

Bhat

Sethi

Sadida

Rah

Mir

Algehainy

Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance

Cancer Metastasis Rev 2024 43 1 197 228 9

Birch

Gil

Senescence and the SASP: many therapeutic avenues

Genes Dev 2020 34 23-24 1565 1576 10

Breitenecker

Homolya

Luca

Lang

Trenk

Petroczi

Down-regulation of A20 promotes immune escape of lung adenocarcinomas

Sci Transl Med 2021 13 601 eabc3911 11

Brenner

Schörg

Ahmetlić

Wieder

Hilke

Simon

Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours

Nat Commun 2020 11 1 1335 12

Bueter

Lee

Rathinam

VAK

Healy

Taron

Specht

Chitosan but not chitin activates the inflammasome by a mechanism dependent upon phagocytosis

J Biol Chem 2011 286 41 35447 35455 13

Burke

Young

IFN-γ: A cytokine at the right time, is in the right place

Semin Immunol 2019 43 101280 14

Cai

Zhong

Cheng

Codelivery of triptolide and IFN-γ to boost antitumor immunity for triple-negative breast cancer

Int Immunopharmacol 2023 120 110346 15

Castro

Pinto

Leite Pereira

Serre

Costa Â

Cavadas

Chitosan/γ-PGA nanoparticles and IFN-γ immunotherapy: A dual approach for triple-negative breast cancer treatment

J Control Release 2025 379 621 635 16

Castro

Pinto

Pereira

Serre

Barbosa

Vermaelen

Chitosan/γ-PGA nanoparticles-based immunotherapy as adjuvant to radiotherapy in breast cancer

Biomaterials 2020 257 120218 17

Chaudhari

Vasu

Golani

Shaikh

Nagariya

Roy

Interferon Induced Upregulation of Tripartite Motif 34 (TRIM34) Leads Apoptotic Cell Death in Lung Adenocarcinoma

J Biochem Mol Toxicol 2024 38 12 e70072 18

Chen

Guo

Shi

Modulation of IFN-γ receptor 1 expression by AP-2α influences IFN-γ sensitivity of cancer cells

Am J Pathol 2012 180 2 661 671 19

Chen

Chou

Liu

Hsieh

Kang

Pang

Induction of metastatic cancer stem cells from the NK/LAK-resistant floating, but not adherent, subset of the UP-LN1 carcinoma cell line by IFN-γ

Lab Invest 2011 91 10 1502 1513 20

Cheon

Wang

Wightman

Jackson

Stark

How cancer cells make and respond to interferon-I

Trends Cancer 2023 9 1 83 92 21

Choi

Huang

Letterio

Kim

Smad4-deficient T cells promote colitis-associated colon cancer via an IFN-γ-dependent suppression of 15-hydroxyprostaglandin dehydrogenase

Front Immunol 2022 13 932412 22

Cillo

Cardello

Shan

Karapetyan

Kunning

Sander

Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity

Cell 2024 187 16 4373 4388 23

Datta

Fracol

McMillan

Berk

Goodman

Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune Monitoring

JAMA Oncol 2016 2 2 242 246 24

Deng

Chen

Long

Song

Xie

Atractylenolides (I, II, and III): a review of their pharmacology and pharmacokinetics

Arch Pharm Res 2021 44 7 633 654 25

Dieterich

Kapaklikaya

Cetintas

Proulx

Commerford

Ikenberg

Transcriptional profiling of breast cancer-associated lymphatic vessels reveals VCAM-1 as regulator of lymphatic invasion and permeability

Int J Cancer 2019 145 10 2804 2815 26

Dieterich

Tacconi

Ducoli

Detmar

Lymphatic vessels in cancer

Physiol Rev 2022 102 4 1837 1879 27

Ding

Wang

Sun

Wang

Role of interferon-gamma (IFN-γ) and IFN-γ receptor 1/2 (IFNγR1/2) in regulation of immunity, infection, and cancer development: IFN-γ-dependent or independent pathway

Biomed Pharmacother 2022 155 113683 28

Ealick

Cook

Vijay-Kumar

Carson

Nagabhushan

Trotta

Three-dimensional structure of recombinant human interferon-gamma

Science 1991 252 5006 698 702 29

Engeland

Cell cycle regulation: p53-p21-RB signaling

Cell Death Differ 2022 29 5 946 960 30

Espinosa-Carrasco

Chiu

Scrivo

Zumbo

Dave

Betel

Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors

Cancer Cell 2024 42 7 1202 1216 31

Falcinelli

Al-Hity

Baron

Mampay

Allen

Samuels

Propranolol reduces IFN-γ driven PD-L1 immunosuppression and improves anti-tumour immunity in ovarian cancer

Brain Behav Immun 2023 110 1 12 32

Gabitova-Cornell

Surumbayeva

Peri

Franco-Barraza

Restifo

Weitz

Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer

Cancer Cell 2020 38 4 567 583 33

Gao

Yang

Cai

Zhang

IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling

Int J Cancer 2018 143 4 931 943 34

Garris

Arlauckas

Kohler

Trefny

Garren

Piot

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

Immunity 2018 49 6 1148 1161 35

Garris

Arlauckas

Kohler

Trefny

Garren

Piot

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

Immunity 2022 55 9 1749 36

Gautam

Elleson

Ramamoorthi

Czerniecki

Current State of Cell Therapies for Breast Cancer

Cancer J 2022 28 4 301 309 37

Giannopoulos

Constantinides

Fokaeas

Stravodimos

Giannopoulou

Kyroudi

The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence

Clin Cancer Res 2003 9 15 5550 5558 38

Gleave

Elhilali

Fradet

Davis

Venner

Saad

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

N Engl J Med 1998 338 18 1265 1271 39

Gocher

Workman

Vignali

DAA

Interferon-γ: teammate or opponent in the tumour microenvironment?

Nat Rev Immunol 2022 22 3 158 172 40

Gordan

Kennedy

Abou-Alfa

Beal

Finn

Gade

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update

J Clin Oncol 2024 42 15 1830 1850 41

Gorgoulis

Adams

Alimonti

Bennett

Bischof

Bishop

Cellular Senescence: Defining a Path Forward

Cell 2019 179 4 813 827 42

Han

Liu

Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy

Front Immunol 2023 14 1190333 43

Hatakeyama

TRIM Family Proteins: Roles in Autophagy, Immunity, and Carcinogenesis

Trends Biochem Sci 2017 42 4 297 311 44

Homann

Rentschler

Brenner

Böhm

Röcken

Wieder

IFN-γ and TNF Induce Senescence and a Distinct Senescence-Associated Secretory Phenotype in Melanoma

Cells 2022 11 9 1514 45

Hosseinzadeh

Imani

Pourfarzi

Jafari

AbedianKenari

Safarzadeh

Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer

Med Oncol 2024 41 5 110 46

Ivashkiv

IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy

Nat Rev Immunol 2018 18 9 545 558 47

Jackson

Jacobs

Arkatkar

Dam

Scharping

Kolhatkar

B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6

J Exp Med 2016 213 5 733 750 48

Jia

Kodumudi

Ramamoorthi

Basu

Snyder

Wiener

Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway

Mol Ther 2021 29 4 1541 1556 49

Johnson

Noon-Song

Ahmed

Controlling Nuclear Jaks and Stats for Specific Gene Activation by Ifn γ and Other Cytokines: A Possible Steroid-like Connection

J Clin Cell Immunol 2011 2 4 1000112 50

Jorgovanovic

Song

Wang

Zhang

Roles of IFN-γ in tumor progression and regression: a review

Biomark Res 2020 8 49 51

Kamoun

de Reyniès

Allory

Sjödahl

Robertson

Seiler

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer

Eur Urol 2020 77 4 420 433 52

Kannan

Raices

Seshadri

Wei

Caligiuri

IκBζ augments IL-12- and IL-18-mediated IFN-γ production in human NK cells

Blood 2011 117 10 2855 2863 53

Kaur

Sassano

Dolniak

Joshi

Majchrzak-Kita

Baker

Role of the Akt pathway in mRNA translation of interferon-stimulated genes

Proc Natl Acad Sci U S A 2008 105 12 4808 4813 54

Kerr

Wyllie

Currie

Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics

Br J Cancer 1972 26 4 239 257 55

Kitamura

Kobayashi

Wakita

Nishimura

Neuropeptide signaling activates dendritic cell-mediated type 1 immune responses through neurokinin-2 receptor

J Immunol 2012 188 9 4200 4208 56

Korentzelos

Wells

Clark

Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer

Sci Rep 2022 12 1 6657 57

Krämer

Knauer

Greiner

Jandt

Reichardt

Gührs

A phosphorylation-acetylation switch regulates STAT1 signaling

Genes Dev 2009 23 2 223 235 58

Kruse

Buzzai

Shridhar

Braun

Gellert

Knauth

CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours

Nature 2023 618 7967 1033 1040 59

Lawrence

Yamashita

Shuman

Raman

Joshi

Yochum

Interferon-γ/Janus Kinase 1/STAT1 Signaling Represses Forkhead Box A1 and Drives a Basal Transcriptional State in Muscle-Invasive Bladder Cancer

Am J Pathol 2025 195 5 1013 1030 60

Yang

Savage

Vincent

de Los Santos-Alexis

Ahn

Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms

Sci Immunol 2024 9 100 eadn9879 61

Liang

Lin

USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axis

Mol Ther 2021 29 6 2108 2120 62

Huang

Qian

Wang

Yuan

Zhang

Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis

Free Radic Biol Med 2024 212 360 374 63

Rao

Xie

Zeng

Isolation, structure and bioactivity of polysaccharides from Atractylodes macrocephala: A review

J Ethnopharmacol 2022 296 115506 64

Dai

Zhao

Jin

Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies

Cancer Res 2024 84 21 3669 3683 65

Lian

Yue

Zhang

Immunosenescence: a key player in cancer development

J Hematol Oncol 2020 13 1 151 66

Liau

NPD

Laktyushin

Lucet

Murphy

Yao

Whitlock

The molecular basis of JAK/STAT inhibition by SOCS1

Nat Commun 2018 9 1 1558 67

Liu

Golji

Brodeur

Chung

Chen

deBeaumont

Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss

Nat Med 2019 25 1 95 102 68

Liu

Yang

Ason

APLNR Regulates IFN-γ signaling via β-arrestin 1 mediated JAK-STAT1 pathway in melanoma cells

Biochem J 2022 479 3 385 399 69

Wang

Jiang

Wang

Chrysin enhances antitumour immunity response through the IL-12-STAT4 signal pathway in the B16F10 melanoma mouse model

Scand J Immunol 2022 96 2 e13177 70

Zong

Chen

Xiang

Xing

TET2-mediated tumor cGAS triggers endothelial STING activation to regulate vasculature remodeling and anti-tumor immunity in liver cancer

Nat Commun 2024 15 1 6 71

Lyden

Ghajar

Correia

Aguirre-Ghiso

Cai

Rescigno

Metastasis

Cancer Cell 2022 40 8 787 791 72

Hostetler

Morgan

Maiorino

Sulkaj

Whittaker

Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity

Cell 2023 186 15 3148 3165 73

Majidpoor

Mortezaee

The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives

Clin Immunol 2021 226 108707 74

Mazet

Mahale

Tong

Watson

Lechuga-Vieco

Pirgova

IFNγ signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells

Nat Commun 2023 14 1 321 75

Mehta

Stanger

Lineage Plasticity: The New Cancer Hallmark on the Block

Cancer Res 2024 84 2 184 191 76

Mendoza

Escalante

Jude

Sotolongo Bellon

Horton

Structure of the IFNγ receptor complex guides design of biased agonists

Nature 2019 567 7746 56 60 77

Mowen

Tang

Zhu

Schurter

Shuai

Herschman

Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription

Cell 2001 104 5 731 741 78

Moyer

Tanaka

Cheng

Apoptosis in Cancer Biology and Therapy

Annu Rev Pathol 2025 20 1 303 328 79

Müller

Christopoulos

Halder

Lunde

Beraki

Speth

Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages

Front Immunol 2017 8 1383 80

Nassar

Blanpain

Cancer Stem Cells: Basic Concepts and Therapeutic Implications

Annu Rev Pathol 2016 11 47 76 81

Niu

Yuan

Sun

Yang

Protein Inhibitor of Activated STAT (PIAS) Negatively Regulates the JAK/STAT Pathway by Inhibiting STAT Phosphorylation and Translocation

Front Immunol 2018 9 2392 82

Nizam

Erin

Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells;Effects independent of Substance P

Biomed Pharmacother 2018 108 263 270 83

Bang

HER2-targeted therapies - a role beyond breast cancer

Nat Rev Clin Oncol 2020 17 1 33 48 84

Hoffmann

González-López

Doherty

Korkola

Muñoz-Espín

Cellular senescence in cancer: from mechanisms to detection

Mol Oncol 2021 15 10 2634 2671 85

Patel

Minn

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies

Immunity 2018 48 3 417 433 86

Pearl

Hsp90 and Cdc37 -- a chaperone cancer conspiracy

Curr Opin Genet Dev 2005 15 1 55 61 87

Pedrosa

Kros

Schrijver

Berrevoets

Marques

van Eijck

T lymphocyte-derived IFN-γ facilitates breast cancer cells to pass the blood-brain barrier: An in vitro study corroborating translational data

Heliyon 2024 10 16 e36598 88

Peng

Liu

Lou

Chen

Yang

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines

Cancer Res 2012 72 20 5209 5218 89

Ping

Shan

Qin

Guo

PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8(+) T cell ferroptosis

Immunity 2024 57 9 2122 2139 90

Platten

von Knebel Doeberitz

Oezen

Wick

Ochs

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors

Front Immunol 2014 5 673 91

Prakash

Praefcke

Renault

Wittinghofer

Herrmann

Structure of human guanylate-binding protein 1 representing a unique class of GTP-binding proteins

Nature 2000 403 6769 567 571 92

Qiu

Ren

Wang

Benci

Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction

Nat Cancer 2023 4 1 43 61 93

Raaby Gammelgaard

Sandfeld-Paulsen

Godsk

Demuth

Meldgaard

Sorensen

cGAS-STING pathway expression as a prognostic tool in NSCLC

Transl Lung Cancer Res 2021 10 1 340 354 94

Reinisch

Holub

Katz

Herneth

Lichtenberger

Schoniger-Hekele

Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma

J Immunother 2002 25 6 489 499 95

Rolfo

Giovannetti

Martinez

McCue

Naing

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer

NPJ Precis Oncol 2023 7 1 26 96

Rydyznski Moderbacher

Kim

Mateus

Plested

Zhu

Cloney-Clark

NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses

J Clin Invest 2022 132 19 e160898 97

Savage

Vincent

Rae

Huang

Ahn

Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity

Sci Adv 2023 9 10 eadc9436 98

Schalper

Carvajal-Hausdorf

McLaughlin

Altan

Velcheti

Gaule

Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer

Clin Cancer Res 2017 23 2 370 378 99

Schmeler

Vadhan-Raj

Ramirez

Apte

Cohen

Bassett

A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer

Gynecol Oncol 2009 113 2 210 215 100

Schoenborn

Wilson

Regulation of interferon-gamma during innate and adaptive immune responses

Adv Immunol 2007 96 41 101 101

Sekrecka

Kluzek

Sekrecki

Boroujeni

Hassani

Yamauchi

Time-dependent recruitment of GAF, ISGF3 and IRF1 complexes shapes IFNα and IFNγ-activated transcriptional responses and explains mechanistic and functional overlap

Cell Mol Life Sci 2023 80 7 187 102

Shan

Han

Shen

Lei

Zhang

Mechanism and strategies of immunotherapy resistance in colorectal cancer

Front Immunol 2022 13 1016646 103

Shen

Huang

Zhang

Ojo

Trummell

Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling

Nat Commun 2022 13 1 5013 104

Shen

Wang

Xiang

Shichi

Nakamoto

Kimura

IFN-γ-STAT1-mediated NK2R expression is involved in the induction of antitumor effector CD8(+) T cells in vivo

Cancer Sci 2023 114 5 1816 1829 105

Shigeta

Matsui

Kikuchi

Klein

Mamessier

Chen

Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma

J Immunother Cancer 2020 8 2 e001435 106

Smith

Chang

Parker

Beury

DuHadaway

Flick

IDO is a nodal pathogenic driver of lung cancer and metastasis development

Cancer Discov 2012 2 8 722 735 107

Smith

Seibel

Altekruse

Ries

Melbert

O'Leary

Outcomes for children and adolescents with cancer: challenges for the twenty-first century

J Clin Oncol 2010 28 15 2625 2634 108

Song

Ping

Zhang

Yang

Zhang

Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer

Cancer Res 2019 79 14 3737 3748 109

Strengell

Matikainen

Sirén

Lehtonen

Foster

Julkunen

IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells

J Immunol 2003 170 11 5464 5469 110

Sun

Nagahama

Singh

Kozakai

Nabeshima

Fukushima

Deletion of the mRNA endonuclease Regnase-1 promotes NK cell anti-tumor activity via OCT2-dependent transcription of Ifng

Immunity 2024 57 6 1360 1377 111

Theivanthiran

Evans

DeVito

Plebanek

Sturdivant

Wachsmuth

A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy

J Clin Invest 2020 130 5 2570 2586 112

Thierfelder

van Deursen

Yamamoto

Tripp

Sarawar

Carson

Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells

Nature 1996 382 6587 171 174 113

Traba

Sack

Waldmann

Anton

Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance

Front Immunol 2021 12 657293 114

Uto

Akagi

Yoshinaga

Toyama

Akashi

Baba

The induction of innate and adaptive immunity by biodegradable poly(γ-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway

Biomaterials 2011 32 22 5206 5212 115

Vahdat

Cohen

Zipin

Donovan

Savage

Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer

Bone Marrow Transplant 2007 40 3 267 272 116

van Mackelenbergh

Loibl

Untch

Buyse

Geyer

, Gianni L, et al. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

J Clin Oncol 2023 41 16 2998 3008 117

Vincent

Gurbatri

Vardoshvili

Coker

Probiotic-guided CAR-T cells for solid tumor targeting

Science 2023 382 6667 211 218 118

Vitale

Shema

Loi

Galluzzi

Intratumoral heterogeneity in cancer progression and response to immunotherapy

Nat Med 2021 27 2 212 224 119

Wall

Burke

Barton

Smyth

Balkwill

IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro

Clin Cancer Res 2003 9 7 2487 2496 120

Wang

Liu

Chen

Koeffler

Tong

Xie

Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers

Cancer Res 2008 68 4 1136 1143 121

Warrick

Sjödahl

Kaag

Raman

Merrill

Shuman

Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants

Eur Urol 2019 75 1 18 22 122

Wawrzyniak

Hartman

Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors

Mol Cancer 2025 24 1 89 123

Wen

Liu

Acharya

Shen

Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice

Nat Commun 2025 16 1 2362 124

Cao

Wang

You

Postoperative Injection of a Triptolide-Preloaded Hydrogel Prevents the Recurrence of Glioblastoma by Dual-Pathway Activation of Ferroptosis

Small 2024 20 50 e2406036 125

Dai

Zhang

Zhu

Liu

Atractylenolide II combined with Interferon-γ synergistically ameliorates colorectal cancer progression in vivo and in vitro by blocking the NF-kB p65/PD-L1 pathway

J Cancer 2024 15 13 4328 4344 126

Xie

Liu

Cai

Huang

Guo

Liang

Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma

Biomed Pharmacother 2023 159 114254 127

Xiong

Yuan

Wang

Fang

IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation

Oncoimmunology 2022 11 1 2044103 128

Zhu

Yin

DNMT3a-mediated methylation of PSTPIP2 enhances inflammation in alcohol-induced liver injury via regulating STAT1 and NF-κB pathway

Pharmacol Res 2022 177 106125 129

Yamazaki

Kiyohara

Uhara

Iizuka

Uehara

Otsuka

Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma

Cancer Sci 2017 108 5 1022 1031 130

Yang

Chen

Zhao

Pan

Peng

Han

Histone deacetylase 3 contributes to the antiviral innate immunity of macrophages by interacting with FOXK1 to regulate STAT1/2 transcription

Cell Rep 2022 38 4 110302 131

Lin

Jiang

Yao

Pan

Xie

Synergistic activity of Enterococcus Faecium-induced ferroptosis via expansion of IFN-γ(+)CD8(+) T cell population in advanced hepatocellular carcinoma treated with sorafenib

Gut Microbes 2024 16 1 2410474 132

Wei

Liu

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Semin Cancer Biol 2022 85 69 94 133

Zaidi

Merlino

The two faces of interferon-γ in cancer

Clin Cancer Res 2011 17 19 6118 6124 134

Zarogoulidis

Ziogas

Boutsikou

Zarogoulidis

Darwiche

Kontakiotis

Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study

Drug Des Devel Ther 2013 7 611 617 135

Zeki

Yavuz

Wood

Shimada

Kaplan

Chiu

Concurrent application of interferon-gamma and vincristine inhibits tumor growth in an orthotopic neuroblastoma mouse model

Pediatr Surg Int 2023 39 1 241 136

Zhan

Zhang

TRIM proteins in lung cancer: Mechanisms, biomarkers and therapeutic targets

Life Sci 2021 268 118985 137

Zhang

Wang

Zhong

Yao

Hepatic Symbiotic Bacterium L. reuteri FLRE5K1 Inhibits the Development and Progression of Hepatocellular Carcinoma via Activating the IFN-γ/CXCL10/CXCR3 Pathway

Probiotics Antimicrob Proteins 2024 16 4 1158 1171 138

Zhu

Bai

Wan

Sun

Lou

IFN-γ-responsiveness of lymphatic endothelial cells inhibits melanoma lymphatic dissemination via AMPK-mediated metabolic control

Biochim Biophys Acta Mol Basis Dis 2024 1870 7 167314 139

Zibelman

MacFarlane

AWt

Costello

McGowan

O'Neill

Kokate

A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors

Nat Commun 2023 14 1 4513

Table 1 IFN-γ exerts antitumor effects through distinct mechanisms across various tumor types Table 2 Clinical trials on IFN-γ for cancer treatment Figure 1 Graphical abstract Figure 2 IFN-γ-producing cells and their associated signaling pathways. T helper 1 (Th1) cells, CD8+ T cells, and NK cells activate PI3K-Akt, p38 MAPK, and STAT1/3/4/5 signaling pathways upon stimulation by macrophage- and dendritic cell (DC)-derived IL-12, IL-15, and IL-18, thereby enhancing the production of IFN-γ. The released IFN-γ further exerts its effect on tumor cells. Figure 3 IFN-γ signaling pathways. 1. JAK-STAT pathway : (1) IFNγR: Transcriptional regulation: NFκB, EGR, and SP1 promote IFNGR mRNA transcription, while AP2 and IRF2 inhibit transcription. (2) JAK: ALPNR is essential for normal JAK function. SOCS proteins and small molecule inhibitors suppress JAK-mediated signaling. (3) STAT1: Transcriptional regulation: STAT1 promoter activity can be suppressed by methylation or activated through HDAC3-mediated deacetylation. Post-translational modifications: PIAS, A20, and CBP/TCP45 inhibit signal transduction activity by dephosphorylating p-STAT1. PRMT1 regulates STAT1 activity/stability independently of its phosphorylation state. p-STAT1 can be degraded via the proteasome pathway. 2. Non-canonical pathway : IFN-γ activates the STAT1-PI3K-Akt axis, thereby recruiting the mammalian target of rapamycin (mTOR) into interferon signaling. Additionally, the mTOR/p70S6 kinase cascade facilitates the mRNA translation of effector proteins. Figure 4 Specific mechanisms involved in the dual role of IFN-γ in exerting both anti-tumor and pro-tumor effects.